Swiss pharma manufacturing giant Siegfried Holding AG has tapped investors for CHF 200 million in fresh funding, locking in low-cost financing as demand surges across the global drug outsourcing market.

 

The company announced that it had successfully placed four-year senior bonds carrying a 1.35% coupon, in a move aimed at reinforcing its balance sheet and preserving firepower for future expansion.

 

The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank, with Siegfried planning to seek listing and trading approval on the SIX Swiss Exchange.

 

“This transaction further strengthens Siegfried’s financial position and maintains strategic flexibility for future growth initiatives. The strong investor response reflects confidence in both our resilient business model and the long-term prospects of the CDMO market," said Chief Financial Officer Reto Suter.

 

The fundraising comes as pharmaceutical companies increasingly outsource manufacturing and development work to specialist CDMOs in a bid to cut costs and accelerate production pipelines.

 

Headquartered in Zofingen, Siegfried operates 16 sites across Europe, the United States, Australia and China. The group manufactures pharmaceutical active ingredients and finished drug products including tablets, capsules, sterile vials and ointments, while also providing development services to the pharma industry.